Synovial tissue macrophages: friend or foe? by Kurowska-Stolarska, Mariola & Alivernini, Stefano
  1Kurowska-Stolarska M, Alivernini S. RMD Open 2017;3:e000527. doi:10.1136/rmdopen-2017-000527
AbstrAct
Healthy synovial tissue includes a lining layer of synovial 
fibroblasts and macrophages. The influx of leucocytes 
during active rheumatoid arthritis (RA) includes 
monocytes that differentiate locally into proinflammatory 
macrophages, and these produce pathogenic tumour 
necrosis factor. During sustained remission, the synovial 
tissue macrophage numbers recede to normal. The 
constitutive presence of tissue macrophages in the lining 
layer of the synovial membrane in healthy donors and 
in patients with RA during remission suggests that this 
macrophage population may have a role in maintaining 
and reinstating synovial tissue homeostasis respectively. 
Recent appreciation of the different origins and functions 
of tissue-resident compared with monocyte-derived 
macrophages has improved the understanding of their 
relative involvement in organ homeostasis in mouse 
models of disease. In this review, informed by mouse 
models and human data, we describe the presence of 
different functional subpopulations of human synovial 
tissue macrophages and discuss their distinct contribution 
to joint homeostasis and chronic inflammation in RA.
Synovial tiSSue homeoStaSiS
Synovial joints link the musculoskeletal system, 
and the joint synovium facilitates movement. 
Bones are linked by the joint capsule and 
collagenous ligaments, and the bone surface 
is covered with articular cartilage that absorbs 
impact. The joint capsule consists of an outer 
fibrous membrane containing ligaments and 
proprioceptive sensory nerves that regulate 
the posture and motion of the joint and an 
inner synovial membrane that produces 
synovial fluid that lubricates the joint during 
movement and nourishes avascular cartilage. 
In healthy people, this complex joint struc-
ture is self-regulated by homeostatic mecha-
nisms to maintain well-functioning articula-
tion, and the synovial membrane is vital for 
maintaining joint homeostasis.1 In rheuma-
toid arthritis (RA), this normal joint structure 
is progressively compromised due to inflam-
mation of the synovial membrane that fails 
to resolve, and this ultimately leads to loss of 
joint function.
The synovial membrane is a highly special-
ised, multifunctional structure consisting of 
two layers: the first is a thin (eg, <2 mm in 
radiocarpal joints by ultrasound imaging)2 
but highly cellular lining layer composed 
of two cell types: synovial fibroblasts and 
synovial macrophages,1 and the second is a 
supporting sublining layer containing loose 
connective tissue with sublining fibroblasts, 
a rich network of sympathetic and sensory 
nerves and blood and lymphatic vasculature 
that provides oxygen/nutrients and immune-
drainage.1 Synovial fibroblasts provide the 
extracellular matrix (ECM) that supports the 
structure of the synovium and secrete hyal-
uronic acid and lubricin into the synovial 
fluid.1 Synovial tissue macrophages (STM) are 
constitutively resident in healthy synovium. 
Their tissue-specific function remains unre-
solved, but this likely includes sentinel joint 
homeostasis. Other immune cells (lympho-
cytes, mast cells and dendritic cells) are scarce 
in the normal synovium and localise mainly in 
perivascular areas of the sublining layer.3
In patients with RA, the synovial membrane 
becomes hypertrophic (eg, 2–5 mm in radio-
carpal joints)2 due to synovial fibroblast 
proliferation, increased blood/lymphatic 
vasculature and an inflammatory influx of 
immune cells from the circulation. The prod-
ucts of these activated cells lead to destruc-
tion of cartilage and bone, pain and loss of 
joint function.4 These changes appear conse-
quential to aberrant homeostatic mechanisms 
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Key messages
 ► There are different macrophage subpopulations 
in the human synovium with the potential to 
contribute either to joint homeostasis or to chronic 
inflammation in rheumatoid arthritis (RA).
 ► experimental models of arthritis support the 
concept that synovial tissue macrophages have a 
pivotal role in reinstating joint homeostasis. 
 ► Deeper understanding of the role of human synovial 
tissue macrophages in the regulation of joint 
homeostasis offers the prospect of new therapeutic 
strategies for RA.
group.bmj.com on December 20, 2017 - Published by http://rmdopen.bmj.com/Downloaded from 
2 Kurowska-Stolarska M, Alivernini S. RMD Open 2017;3:e000527. doi:10.1136/rmdopen-2017-000527
RMD Open
that fail to resolve inflammatory synovitis. Understanding 
synovial homeostasis may offer the prospect of new therapeutic 
strategies for RA.
Synovial tiSSue inflammation and reSolution in ra
RA is the most common inflammatory arthropathy, 
affecting approximately 0.4 million people in the UK,5 
causing morbidity and reduced quality of life and 
represents a substantial socioeconomic and healthcare 
burden. An interplay between genetics (>100 loci), envi-
ronmental factors (eg, cigarette smoking and occupa-
tional exposure to silica) and alterations in the mucosal 
microbiome can contribute to the development of RA.6 7 
Clinical RA is preceded by an asymptomatic preclinical 
breach of tolerance to citrullinated self-peptides, activa-
tion of autoreactive T cells and production of anticitrulli-
nated peptide-specific antibodies (ACPA). Joint injury or 
other poorly defined events can then lead to activation 
of the synovial tissue vasculature permitting localisation 
of ACPA immune complexes in the synovium. These 
complexes activate synovial tissue fibroblasts and bone 
cells (osteoclasts) and perpetuate the influx of leuco-
cytes, for example, neutrophils, monocytes, Th1/Th17 
and B cells. These cells are activated by local stimuli (eg, 
endogenous Toll-like receptors (TLR) ligands, proinflam-
matory cytokines and hypoxia), further modulated by 
genetic and epigenetic modifications of gene expression 
to propagate the synovitis. Depending on the dominant 
cellular component and distinct molecular pathogenic 
pathways, RA synovitis can be characterised as myeloid 
(macrophage rich), lymphoid (containing T/B cell folli-
cles) and fibroid (leucocyte low) 4 8 (comprehensive reviews 
on mechanisms and type of synovitis). Emerging data suggest 
that this underlying cellular heterogeneity in RA may 
influence the clinical outcome to therapies targeting 
different biological pathways.9
Recent advances in RA therapies mainly target the medi-
ators of inflammation (eg, tumour necrosis factor (TNF), 
interleukin (IL)-6R and janus kinase (JAKs)), or block 
the adaptive immune response (eg, T cell stimulation or 
B cell function). These therapies are life-long, expensive 
and offer inadequate responses in 30%–50% of patients 
with RA.7 10 Furthermore, of those who respond, approx-
imately half will relapse within months of treatment 
cessation and few achieve long-term remission with resto-
ration of joint function.10 11 Remission of RA is defined by 
sustained resolution of swollen and painful joints and by 
normalised biomarkers of inflammation. These include 
erythrocyte sedimentation rate, which contributes to a 
low disease activity score of 44 joints of less than 1.6,12 
and resolution of synovial inflammation confirmed by 
normal blood flow (by Power Doppler ultrasound).2 11 
Early remission can stop the substantial cartilage loss and 
rebalance bone turnover, which are key in recovering 
joint function.11 13 14 The fact that some patients sustain 
drug-free remission is proof of concept that immunolog-
ical homeostasis and healthy joint remodelling can be 
reinstated in RA. Therefore, understanding homeostatic 
mechanisms in these patients could help to develop ther-
apeutic strategies to reinstate synovial homeostasis in RA. 
Experimental models of arthritis support the concept 
that STMs have a pivotal role in this process.15
Stm SubpopulationS
The functions of macrophages in joint synovial tissue of 
healthy subjects are poorly described. In RA, most knowl-
edge of synovial myeloid cells is derived from studies of 
monocytes from RA synovial fluid that contribute to local 
production of inflammatory and joint-degrading media-
tors.16–18 However, monocytes are not present in the syno-
vial fluid from healthy subjects19 and from patients with 
RA in remission.20
STMs are the most common resident immune cells 
in the healthy synovial membrane,21 and dendritic cells 
and lymphocytes are scarce. In active RA with myeloid 
and lymphoid synovitis, the synovial membrane is leuco-
cyte-rich, including an increased number of proinflam-
matory macrophages that likely differentiate locally from 
blood monocytes attracted to synovial tissue and fluid by 
local chemokines,22 and these macrophages are the main 
producers of pathogenic TNF.4 11 17 In remission, most 
of the synovial inflammation resolves, but STMs in the 
lining layer persist.11 It would be important to establish 
if these macrophages have the same phenotype as those 
in healthy synovium. The constitutive presence of tissue 
macrophages in healthy synovial tissue and the sustained 
presence in patients with RA during remission suggests 
that these subpopulations of STMs may have a role in 
synovial homeostasis.11
the ConCept of tiSSue-reSident and monoCyte-derived 
maCrophageS
Mouse models show that most healthy organs contain 
tissue-resident macrophages that originate from 
prenatal precursors and are essential for maintaining 
immune homeostasis and intact organ function. In 
response to inflammation, a different tissue macrophage 
population differentiates from monocytes that migrate 
transiently from the circulation. The relative roles of 
these macrophage populations determine chronicity or 
resolution of inflammation.23
The ontogeny and precise role of human STMs in 
joint homeostasis are unknown. Animal studies suggest 
that mouse resident STMs are of prenatal origin and can 
proliferate locally in the tissue, whereas synovial tissue 
proinflammatory macrophages differentiate from either 
of two subpopulations of blood monocytes (Ly6Cpos and 
Ly6Cneg) that traffic into the inflamed synovium depen-
dent on the nature of the trigger of the joint inflamma-
tion.15 24 The Ly6Cneg patrolling monocytes differentiate 
into proinflammatory macrophages that mediated joint 
pathology in an antibody transfer model of arthritis, while 
Ly6Cpos classical monocytes gave rise to synovial macro-
phages that drive inflammation in adjuvant-induced and 
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Figure 1 The role of synovial tissue macrophages in arthritis. (A) The mouse synovium contains major histocompatibility 
complex (MHC) class II negative (MHC-II−) tissue-resident macrophages that originate from prenatal precursors and have 
the capacity to proliferate. On induction of experimental arthritis, there is an influx of monocytes (Ly6C+or Ly6C−, depending 
of the nature of the induction) that differentiate into MHC class II positive (+) proinflammatory macrophages that mediate 
joint pathology. Resolution of arthritis is associated with a phenotypic change of the monocyte-derived macrophages from 
proinflammatory to anti-inflammatory, along with the contribution of tissue-resident macrophages. (B) In humans, the synovial 
membrane of healthy subjects and of patients with RA in sustained remission contain macrophages in the lining layer. Their 
origin and function are unknown. In patients with active arthritis, the CD14+ subpopulation of infiltrating monocytes contributes 
to the increased MHC-II+ proinflammatory macrophage pool in the inflamed synovium. Proinflammatory macrophages of 
patients with arthritis produce a broad range of inflammatory mediators, and their phenotype is maintained by the miR-155/
SHIP-1 pathway. PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; RA, rheumatoid arthritis; SHIP-1, phosphatidylinositol-
3,4,5-trisphosphate 5-phosphatase 1; TLR, Toll-like receptors.
antigen-induced arthritis.24 It is likely that the differ-
ence in chemokines induced by immune complexes or 
adjuvant in these models were responsible for attracting 
different populations of monocytes into the joints. In 
vivo tracking of labelled blood monocytes (CD14+ popu-
lation that resembles mouse Ly6C+) in patients with 
RA has confirmed their migration into the inflamed 
synovium where they add to the tissue macrophage pool 
during inflammation.25 26 The traffic of other monocyte 
subpopulations into and within synovial tissue remains to 
be confirmed (figure 1).
The distinct functions of mouse tissue-resident and 
monocyte-derived macrophage populations in animal 
models of disease have improved our understanding of 
organ homeostasis.27 Tissue-resident macrophages can 
be self-renewing, controlled by the transcription factor 
Gata6, and maintain tissue immune homeostasis,28 
whereas monocyte-derived macrophages predominate 
and drive inflammation in chronic disease models.15 29 
Successful resolution of inflammation and reinstatement 
of tissue homeostasis requires differentiation of these 
proinflammatory macrophages towards an anti-inflam-
matory phenotype, and the activation/expansion of 
resident tissue macrophages15 29 30 that synergise for 
tissue homeostasis by production of anti-inflammatory/
immune regulatory mediators (eg, resolvins, IL-10 and 
transforming growth factor beta (TGFβ)).31–33 In addi-
tion, tissue-resident macrophages contribute to tissue 
remodelling by removing apoptotic cells (efferocy-
tosis), metabolic products and damaged tissue compo-
nents34–37 and by reinstating tissue spatial organisation, 
for example, pigment cell distribution in zebrafish 
skin.38 In addition to the shared immune regulatory 
functions, mouse tissue-resident macrophages show 
tissue-specific homeostatic properties that are deter-
mined by the physiological needs of their specific envi-
ronment. Tissue-resident macrophage differentiation 
and function is governed by tissue-specific cues and ‘on 
demand’ signals. Examples of these have been shown in 
an elegant study by van der Laar and colleagues in which 
either yolk-sac macrophages, fetal liver macrophages 
or bone marrow monocytes, on transfer into empty 
lung alveolar niches, indistinguishably differentiated 
into alveolar macrophages with the characteristic local 
functional regulation of lung surfactants.39 Transfer 
of mature macrophages from other tissues could not 
replicate this differentiation, thus confirming that the 
plasticity of macrophage maturation is optimal at the 
precursor stage and that tissue-specific cues determine 
local macrophage specialisation.
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Figure 2 What is the tissue-specific function of synovial-resident macrophages? Tissue-specific functions of resident-tissue 
macrophages are induced by local cues. Their function in the synovium is unknown, but we can speculate by reference to 
other tissues. In the lung, for example, the differentiation of alveolar macrophages is driven by lung epithelial cell-derived GM-
CSF, and recycling of surfactant is regulated by transcription factor PPARγ. Deficiency of alveolar macrophages, GM-CSF or 
PPARγ leads to pulmonary proteinosis. Spleen red pulp macrophages specialised in iron-recycling. This function is induced by 
heme derived from erythrocyte degradation and executed by BACH2 and SPIC. Selective deficiency of red pulp macrophages 
(deficiency of SPIC) leads to aberrant iron metabolism. Osteoclasts are bone macrophages that specialise in bone degradation. 
Their functional programme is induced by RANKL and executed by multiple transcription factors, including NFATC1. Deficiency 
in functional osteoclasts (RANKL−/− or M-CSF-−/−) leads to an increase in bone mass (osteopetrosis). Speculatively, in healthy 
joints, synovial tissue macrophages may specialise in recycling lubricin, the lubricating components of synovial fluid and in 
providing regulatory factors for cartilage and bone turnover. BACH2, transcription regulator protein BACH2; FLS, fibroblast-like 
synoviocytes; GM-CSF, granulocyte macrophage colony-stimulating factor; M-CSF, macrophage colony-stimulating factor; MQ, 
macrophages; NFATC1, nuclear factor of activated T cells, cytoplasmic 1;  PPARγ, peroxisome proliferator-activated receptor 
gamma; RANKL, receptor activator of nuclear factor kappa-B ligand; SPIC, transcription factor Spi-C.
These tissue-specific cues include a combination of cell 
contact and soluble factors.40 These have not been delin-
eated in the synovium, but equivalent examples have 
been described in other tissues (figure 2), for example, 
direct contact with neurons is required for macrophage 
precursors to develop into microglia.41 The tissue-soluble 
factors include cytokines and tissue breakdown products. 
The differentiation of alveolar macrophages requires 
lung epithelial cell-derived granulocyte macrophage 
colony-stimulating factor (GM-CSF) and the induction of 
the transcription factor peroxisome proliferator-activated 
receptor gamma (PPARγ) that contributes to tissue-spe-
cific local function by regulating lung surfactants.42 The 
local differentiation of spleen red pulp macrophages 
requires the transcription factor BACH1 that recog-
nises heme from erythrocyte degradation and induces 
their specialised iron-recycling function.43 Retinoic acid 
produced by the omentum is key in the differentiation 
of peritoneal macrophages that function to control 
IgA production by B-1 cells,44 and receptor activator of 
nuclear factor kappa-B ligand (RANKL) expressed in 
bone osteoblasts drives the differentiation of macro-
phages (osteoclasts) with bone-resorbing function.45 A 
combination of these tissue-specific cues and transient 
‘on-demand’ signals, (eg, tissue injury creates signals 
to remove apoptotic inflammatory cells)32 37 induces 
programmes that are common for all tissue macrophages 
or programmes that are specific for a particular tissue. 
These programmes enable cells to perform general 
immune homeostatic functions, for example, Mer tyro-
sine protein kinase receptor (MerTK)-mediated efferocy-
tosis and production of anti-inflammatory resolvins,32 37 
or tissue-specific functions, for example, iron recycling 
by the spleen macrophages.46 These tissue-specific 
transcriptomic programmes are coordinated by specific 
transcription factors, for example, SPIC46 in spleen red 
pulp, LXRα47 in spleen marginal zone, PPARγ42 and 
Bach248 in alveolar macrophages, GATA634 in peritoneal 
macrophages and NR4A149 in thymic macrophages. 
These cooperate with macrophage lineage master regu-
lator transcription factors such as PU.1 induced by macro-
phage colony-stimulating factor (M-CSF)/IL-34 that 
maintain universal macrophage-specific gene expres-
sion.50 Alveolar macrophage deficiency in humans and 
mice results in pulmonary alveolar proteinosis caused by 
the progressive accumulation of surfactant,39 51 and mice 
deficient in functional spleen red pulp macrophages 
develop a disorder of iron homeostasis.46 These examples 
illustrate the critical role of tissue-resident macrophages 
in the maintenance of tissue homeostasis (figure 2).
human homeoStatiC StmS: friend
The diversity of human STMs in health and disease is 
poorly described, while their tissue-specific functions 
are unknown. In healthy joints, STMs are located on the 
surface of the synovial membrane and are in contact with 
synovial fluid, suggesting that they may specialise in recy-
cling the lubricating components of synovial fluid (analo-
gous to alveolar macrophage recycling surfactant) and in 
providing regulatory factors for cartilage and bone turn-
over. Similar to other tissue-resident macrophages, they 
may also remove cell debris and pathogens to prevent 
sterile and septic inflammation. We review here the 
evidence for the potential homeostatic role of human syno-
vial tissue-resident macrophages. Most of these data are 
historical and/or based on immunohistochemistry and is 
therefore of limited functional and molecular resolution. 
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Early studies described three subtypes of STMs distin-
guishable by staining with 25F9, 27E10 and RM3/1 anti-
body clones. Their tissue distribution differed depending 
on whether the synovial tissue was normal, inflamed or 
resolving in studies on septic arthritis52 suggesting that 
they had distinct functions. In patients with osteoarthritis 
the 25F9+ macrophages predominated in the non-in-
flammatory synovium53 and in the non-inflamed areas in 
the synovium of septic arthritis,52 whereas macrophages 
in the inflamed areas in the synovium of septic arthritis 
were 27E10+.52 The latter also dominated in the syno-
vial tissues of patients with active RA (more information 
in the next section).54 25F9+ macrophages abundantly 
expressed IL-1R antagonist,53 suggesting an anti-inflam-
matory function. In healthy joints, most STMs contained 
phagosomes and were RM3/1+ (now known to recognise 
the scavenger receptor CD163), suggesting that they 
are strongly phagocytic.3 55 They also expressed major 
histocompatibility complex (MHC)-II, IL-1R antagonist 
and the inhibitor of bone degradation, osteoprotegerin 
(OPG),3 21 56 and they were negative for proinflammatory 
cytokines (eg, TNF and IL1β) and the bone resorption 
cytokine RANKL,56 suggesting a joint protective func-
tion against inflammation and damage. Furthermore, in 
contrast to inflamed joints, these macrophages colocalise 
with mesenchymal progenitor cells57 suggesting a role in 
regulating repair.
These observations indicate the presence of subsets 
of tissue macrophages with functional characteristics 
suggesting a potential homeostatic role controlling 
inflammation, maintaining tissue integrity and bone 
protection, thus preserving healthy joint structure and 
function.11 Experimental models of arthritis support 
this hypothesis. Healthy mouse synovium contains a 
tissue-resident macrophage population that has a gene 
signature distinct from monocyte-derived macrophages. 
This includes expression of inhibitors of inflamma-
tion, SHIP-1 and MerTK, and these macrophages were 
crucial in preventing inflammatory responses in mouse 
synovium and in resolution of arthritis in the antibody 
transfer arthritis model.15 24 These data support the 
concept that joint immune homeostasis could be rein-
stated by distinct STM subpopulation.
human inflammatory StmS: foe
In active RA, fuelled by an influx of blood monocytes,26 
the total number of STMs increased in all types of syno-
vitis,9 particularly in the sublining layer of myeloid and 
lymphoid types. They are predominantly proinflam-
matory and produce CXCL4 and CXCL7 (chemokines 
recruiting neutrophils and blood monocytes) particularly 
in early RA,22 and TNF58 and other pro-inflammatory 
cytokines (IL-15,59 IL-1β,53 IL-6, GM-CSF and TGFβ60) 
throughout disease progression. These macrophages 
are 27E10+, which recognises an epitope on the alarmins 
S100A8/9.61 These S100A8/9+ macrophages are suscep-
tible to anti-TNF therapy54 after which they are removed 
by rapid efflux.26 RM3/1 (CD163) macrophages, typi-
cally found in healthy joints, are also present in RA 
synovium. They were found to be localised far from IFNγ 
positive T cells,62 and their numbers were unaffected 
by anti-TNF therapy54 suggesting that they have distinct 
functions. Historical ex vivo functional studies demon-
strated that total macrophages isolated from active RA 
synovial tissue spontaneously released proinflamma-
tory mediators (eg, TNF, IL-1β, IL-6,63 CXCL864 and 
CCL265) and are able to stimulate autologous T cells.66 
Staining of these macrophages with the antibody recog-
nising CD13, expressed on bone marrow-derived myeloid 
cells, alluded to the presence of at least two function-
ally distinct subpopulations that differed in their angi-
ogenic properties. Only macrophages that were CD13 
positive promoted angiogenesis, implying a role in vascu-
larisation and hyperplasia of the RA synovium.67 68
The activation of proinflammatory macrophages 
in humans and mice is governed by the transcription 
factors NFκB, IRF5 and STAT1/569 70 and is maintained 
by microRNA-155. We showed that increased miR-155 
prevented the translation of its mRNA epigenetic target 
SHIP-1, and thereby removed its negative feedback 
control of inflammatory TLR and PI3K signalling, thus 
permitting sustained production of cytokines and chemo-
kines by these macrophages.17 71 Most RA STMs express 
high levels of miR-155 and commensurately low levels of 
SHIP-1, which is in sharp contrast to macrophages from 
non-inflamed synovium where the majority lack miR-155 
and have high expression of SHIP-117 (figure 3).
Together these data provide evidence for different 
macrophage subpopulations in human synovium with poten-
tially homeostatic or inflammatory properties. However, the 
prospect of therapeutic translation of the homeostatic 
potential of STM subpopulations requires more precise 
understanding of their phenotypic heterogeneity and 
function. The rapid progress in using synovial tissue 
biopsy to study disease pathogenesis72 and the current 
advances in a single cell sequencing73 could help to 
reveal their biology.
potential tiSSue-SpeCifiC ‘CueS’ and ‘on demand’ 
determinantS of Synovial tiSSue maCrophage 
homeoStatiC and inflammatory funCtionS
Okabe and Medzhitov proposed a model in which the 
tissue-resident macrophage phenotype is determined 
by core transcriptomic modules induced, for example, 
by M-CSF/PU.1 that are common for all macrophages. 
Thereafter, tissue-specific transcriptomic modules 
are induced by tissue ‘cues’ (eg, GM-CSF in alveolar 
macrophages) that determine tissue-specific function 
(eg, recycling of surfactant in the lung) to maintain 
organ-specific homeostasis. Changes in the local environ-
ment, for example, infection or tissue injury, induce ‘on 
demand’ modules to eliminate the stressor, for example, 
chemokine production, to initiate the recruitment of 
neutrophils and monocytes that become a source of 
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Figure 3 What are the effector pathways, transcriptional regulators and activators of synovial tissue macrophages in healthy 
donors and in patients with RA in remission? The constitutive presence of tissue macrophages in healthy synovial tissue 
and the sustained presence of some synovial tissue macrophages in patients with RA during remission suggests that these 
subpopulations have a role in maintaining and reinstating synovial homeostasis. However, little is known about the effector 
pathways and stimuli and transcription factors that execute their function. Synovial tissue macrophages in healthy subjects 
express the scavenger receptor CD163, suggesting that they are strongly phagocytic. They also express MHC-II, IL-1R-
antagonist and the inhibitor of bone degradation, osteoprotegerin (OPG), and they are negative for proinflammatory cytokines 
(eg, TNF and IL1β) and the bone resorption cytokine RANKL, suggesting a joint protective function against inflammation 
and damage. In contrast, the phenotype of proinflammatory synovial tissue macrophages is well described. These cells are 
MHC-II positive and produce a broad range of inflammatory mediators (eg, TNF, IL1β, IL-6, IL-23 and S100A8/9) that drive 
local and systemic pathologies in RA. Their activation is sustained by a variety of local stimuli that include endogenous TLR 
ligands, immune complexes, oxidised lipids, hypoxia and integrin-mediated contact with synovial fibroblasts and T cells. This 
proinflammatory programme is executed by NFκB, IRF5, STAT1/5 and HIF1α and is maintained by microRNA-155. FcγR, 
Fc gamma receptor; GM-CSFR, granulocyte macrophage colony-stimulating factor receptor; IL, interleukin; IRF, interferon 
regulatory factor; LXRα, liver X receptor alpha; NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; RA, 
rheumatoid arthritis; STAT, signal transducer and activator of transcription; TLR, Toll-like receptors; TNF, tumour necrosis factor.
inflammatory macrophages74 or efferocytosis37 to facili-
tate the reinstatement of tissue homeostasis at the later 
stages of inflammation.32 40
The tissue-specific cues determining the phenotype 
and transcriptomic programme of synovial tissue-res-
ident macrophages in health and those present in 
patients with RA in remission are unknown. Local differ-
entiation of microglia requires direct contact of primi-
tive macrophage precursors with neurons,41 therefore 
by analogy, the interaction of macrophage precursors 
with lining synovial fibroblasts that undergo biomechan-
ical stretch may trigger their local differentiation into 
synovial tissue-resident macrophages. The characteristic 
ECM produced by synovial fibroblasts (eg, lubricin and 
hyaluronic acids), by analogy to the profound impact of 
ECM produced by lung fibroblasts on the transcriptome 
of recruited myeloid cells,75 76 could affect macrophage 
differentiation and survival by binding to macrophage 
CD4476 or TLR2.77 Uncovering the transcriptomic 
programme, molecular regulators and cues that drive 
synovial tissue-resident macrophage function will aid the 
understanding of mechanisms of joint homeostasis and 
provide novel therapeutic approaches to reinstate joint 
immune homeostasis in patients with arthritis.
In the tissue environment of the RA synovium, 
tissue-specific cues are modulated by tissue injury and 
proinflammatory ‘on-demand’ signals, which mobilise 
monocytes and instruct their differentiation to mono-
cyte-derived pro-inflammatory macrophages.4 71 78 79 It 
is unknown whether distinct human tissue-resident and 
monocyte-derived synovial tissue macrophage subpopula-
tions would respond differently to the synovial tissue-spe-
cific and ‘on demand’ proinflammatory cues (figure 4). 
In mouse tissues, recruitment of blood monocytes in 
response to ‘on-demand’ signal is often concomitant with 
a loss of tissue-resident macrophages due to emigration 
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Figure 4 Putative contribution of tissue-specific (signal 1) and the local polarisation environment (signal 2) to the phenotype 
of synovial tissue macrophages in homeostasis and inflammation. Tissue-specific cues (signal 1), for example, from stretched 
synovial fibroblasts (FLS) to macrophage precursors may induce the synovial tissue macrophage programme that maintains 
synovial homeostasis. In the inflamed RA synovium, tissue-specific cues are modulated by proinflammatory on-demand signals 
(signal 2; eg, provided by epigenetically changed FLS, leucocytes and hypoxia). Most understanding is based on experimental 
models, and it is unknown whether distinct human synovial tissue macrophage subpopulations would respond differently to 
the synovial tissue-specific and ‘on-demand’ proinflammatory cues. Dissecting these pathways will improve our understanding 
of the mechanisms of successful versus failed joint homeostasis. MC, mast cells; ; MQ, macrophages; Neu, neutrophils; TF, 
transcription factor; Th17/Th1, T helper 1 and 17.
or death.80 In the synovium of active patients with RA, 
both S100A8/9+and CD163+macrophages are present, 
although the latter in much lower numbers.54 Similarly, 
in mouse models of arthritis, tissue-resident macrophages 
were present at the peak of inflammation, along with 
monocyte-derived macrophages, although outnumbered 
and with distinct transcriptomic profiles. For example, 
monocyte-derived macrophages expressed high levels of 
proinflammatory mediators, for example, IL-1β, IL-12, 
CD80 and CD86, compared with resident macrophages, 
while the latter upregulated efferocytosis receptors.15 This 
suggests that, at least in the mouse, tissue-resident and 
monocyte-derived macrophages may respond differently 
to ‘on demand’ signals. In RA synovium, the phenotype of 
monocyte-derived macrophages is shaped by the interac-
tion with synovial fibroblasts that are epigenetically repro-
grammed to produce a wide range of mediators,81 for 
example, GM-CSF that potentiates the proinflammatory 
activation of macrophages.82 83 In addition, danger-asso-
ciated molecular pattern molecules (DAMPs) released in 
the damage joint, for example, tenascin-C, bind to TLR4 
and trigger proinflammatory cytokine production by 
macrophages.84 ACPA produced locally in lymphoid type 
of synovitis forms immune complexes with citrullinated 
fibrinogen and induces TNF production via synergistic 
binding to FcγR and TLR4.85 Oxysterols, enriched in RA 
synovial fluid, bind to LXRα in synovial macrophages and 
enhance DAMPs-induced TNF, IL-6 and IL-1β produc-
tion.86 Memory T cells, recruited and expanded in syno-
vial fluid by cytokines (eg, IL-15, IL-6 and TNF), trigger 
substantial production of TNF by macrophages on direct 
integrin-mediated contact,87 88 while IFNγ released by RA 
citrullinated peptide autoreactive T cells89 enhances the 
ability of macrophages to present antigen and thereby 
their potential to activate autoreactive memory T cells. 
The hypertrophic synovium creates a hypoxic environ-
ment,90 and recruited macrophages adapt by changing 
their metabolism and phenotype. This response, 
mediated by hypoxia inducible transcription factor 1 
(HIF-1α), leads to an increased production of proinflam-
matory cytokines and can redirect differentiation towards 
bone-resorbing osteoclasts.91 For example, HIF-1α abro-
gates the mTORC1/IL-10-induced negative feedback 
mechanism of macrophage activation92 while stimulating 
IL-1β production.93 In addition, hypoxia decreases the 
expression of COMMD1 (an inhibitor of macrophage to 
osteoclast differentiation) and can thereby facilitate syno-
vial macrophage-driven pathogenic bone resorption.91
Many of these signals increase the expression of 
miR-155, which locks the macrophages in a proinflam-
matory state.17 94 In mouse models of arthritis, at some 
time-point, there is a phenotypic change of monocyte-de-
rived macrophages from proinflammatory to anti-inflam-
matory, which is induced by an as-yet unidentified signal. 
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This phenotypic change in monocyte-derived macro-
phages and the functions of tissue-resident macrophages 
are required for the resolution of arthritis.15
In RA, the role of recruited synovial macrophages in 
mediating remission of disease is uncertain. The obser-
vation that alleviation of disease with anti-TNF therapy 
leads to a decrease of joint-infiltrating S100A8/9+ macro-
phages,26 presumably by enhanced efflux of these 
cells from the synovium,26 while the number of poten-
tial resident-tissue (CD163+) macrophages remained 
unchanged54 would argue against an active role of mono-
cyte-derived macrophages in the resolution of RA.
Summary
There is evidence for the presence of different subpop-
ulations of synovial tissue macrophages with potentially 
distinct homeostatic versus inflammatory functions. 
While synovial macrophage inflammatory pathways are 
relatively well described and therapeutically targeted, 
little is known about the synovial tissue macrophages 
constitutively present in healthy subjects and persistent 
in patients with RA during sustained remission. Under-
standing the biology of these cells could help to reveal 
the mechanisms of synovial immune homeostasis and 
could offer the prospect of novel strategies for treatment 
of joint diseases.
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